EN 中文
Home
About us
Values of Xizimed Experience of Xizimed
Businesses
Focus
Our News Industry Events
Training
Careers
Contact Us
Focus Current location:Home > Focus
Copy | Announcement of NMPA on the Issuance of the Administration of Post-approval Changes to Drugs (Trial Implementation) (No. 8 in 2021)

  为贯彻《药品管理法》有关规定,进一步加强药品上市后变更管理, 药监局组织制定了《药品上市后变更管理办法(试行)》,现予发布,自发布之日起施行,此前规定与本公告不一致的,以本公告为准。
  各省级药品监管部门应当落实辖区内药品上市后变更监管责任,细化工作要求,制定工作文件,明确工作时限,药品注册管理和生产监管应当加强配合,互为支撑,确保药品上市后变更监管工作平稳有序开展。
  特此公告。
  附件:1.药品上市后变更管理办法(试行)
     2. 关于实施《药品上市后变更管理办法(试行)》的说明
     3. 《药品上市后变更管理办法(试行)》政策解读
     4. 药品上市许可持有人变更申报资料要求
  

                                     

                                                                                                                                                                                                                                         药监局
                                                                                                                                                                                                                                                                    2021年1月12日

Previous article:Copy | Notice on the Requirements for Submissions in Electronic Format of Drug Registration Next article:Copy |Announcement of NMPA on the Re-issuance of the Fee Standards for Drug Registration (No. 75 in 2020)
Contact
Tel: +86-24-31699170
Address:Room 1713, Building A, China Merchants Tower, 7-2 Yingpan North Street, Hunnan District, Shenyang, China
Address:608, Building A, Tongzhou Wanda Plaza, Tongzhou District, Beijing, China

Record No.: Liao ICP Record No. 2022008769-2
About us
Experience of Xizimed Values of Xizimed
Focus
Our News Industry Events
Scan QR code Scan the code

HOME

Business

TEL